Attached files

file filename
8-K - FORM 8-K - ZIMMER BIOMET HOLDINGS, INC.c65607e8vk.htm
Exhibit 99.1
Contacts:
         
 
  Media   Investors
 
  Garry R. Clark   Robert J. Marshall Jr.
 
  574-372-4493   574-371-8042
 
  garry.clark@zimmer.com   robert.marshall@zimmer.com
Zimmer Holdings, Inc. Reports Second Quarter 2011 Financial Results
    Net Sales of $1,137 million for the second quarter represent an increase of 7.5% reported (2.1% constant currency) over the prior year period
 
    Diluted EPS for the second quarter were $1.06 reported, an increase of 29.3% over the prior year period, and $1.21 adjusted, an increase of 11% over the prior year period
 
    Company updates full-year sales and EPS guidance
(WARSAW, IN) July 27, 2011—Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported financial results for the quarter ended June 30, 2011. The Company reported second quarter net sales of $1,137 million, an increase of 7.5% reported and 2.1% constant currency over the second quarter of 2010. Diluted earnings per share for the quarter were $1.06 reported and $1.21 adjusted, an increase of 11% adjusted over the prior year period.
“Zimmer again generated solid results in the second quarter, amid ongoing challenging global economic conditions,” said David Dvorak, Zimmer President and CEO. “Our results reflect improved sales execution in support of new product introductions across our diverse geographic channels, as well as the positive impact of operational improvement initiatives and continued disciplined capital deployment.”
Net earnings for the second quarter were $203.8 million on a reported basis and $232.5 million on an adjusted basis, an increase of 5.1% adjusted over the prior year period. Operating cash flow for the second quarter was $251.0 million.

1


 

In the second quarter, the Company recorded an additional $50 million provision for known and anticipated worldwide claims related to the previously announced voluntary suspension of marketing and distribution of the Durom® Acetabular Component in the United States. Adjusted 2011 figures in this release exclude the impact of this provision.
During the quarter, the Company utilized $121 million of cash to acquire 1.8 million shares. At the end of the second quarter, $848.6 million of share repurchase authorization remained available under the current program, which expires on December 31, 2013.
Guidance
The Company updated its full-year revenue and adjusted EPS guidance for 2011. Full-year revenues for 2011 are now expected to increase between 2.5% and 3.5% on a constant currency basis from 2010. The Company estimates that foreign currency translation will increase revenues by approximately 3% for the full year 2011, resulting in reported revenue growth between 5.5% and 6.5%. This compares with prior revenue guidance of 2.0% to 4.0% constant currency and 5.0% to 7.0% reported growth over prior year. Full-year 2011 diluted earnings per share are now projected to be in a range of $4.25 to $4.35 on a reported basis and $4.70 to $4.80 on an adjusted basis, which represents a narrowing toward the top end of prior adjusted earnings guidance.
Conference Call
The Company will conduct its second quarter 2011 investor conference call today, July 27, 2011, at 8:00 a.m. Eastern Time. The live audio webcast can be accessed via Zimmer’s Investor Relations website at http://investor.zimmer.com. It will be archived for replay following the conference.
Individuals who wish to dial into the conference call may do so at (888) 878-3901. International callers should dial (706) 634-9520. A digital recording will be available two hours after the completion of the conference call from July 27, 2011, to August 10,

2


 

2011. To access the recording, US/Canada callers should dial (800) 642-1687, or for International callers, dial (706) 645-9291, and enter the conference ID 76248595.
Sales Tables
The following tables provide sales results by geographic segment and product category, as well as the percentage change compared to the prior year quarter and six months on both a reported and constant currency basis.

3


 

NET SALES — THREE MONTHS ENDED JUNE 30, 2011
(in millions, unaudited)
                         
                    Constant  
    Net     Reported     Currency  
    Sales     % Growth     % Growth  
Geographic Segments
                       
Americas
  $ 608       %     %
Europe
    325       17       5  
Asia Pacific
    204       19       6  
 
                     
Total
    1,137       8       2  
 
                       
Product Categories
                       
Reconstructive
                       
Americas
    449       (2 )     (2 )
Europe
    257       16       4  
Asia Pacific
    151       17       4  
 
                     
Total
    857       6        
 
                       
Knees
                       
Americas
    266       (5 )     (5 )
Europe
    128       21       9  
Asia Pacific
    77       14       2  
 
                     
Total
    471       4       (1 )
 
                       
Hips
                       
Americas
    151       2       2  
Europe
    122       12       (1 )
Asia Pacific
    72       20       7  
 
                     
Total
    345       9       2  
 
                       
Extremities
    41       7       4  
 
                       
Dental
    67       20       16  
 
                       
Trauma
    69       20       14  
 
                       
Spine
    56       (3 )     (6 )
 
                       
Surgical and other
    88       13       8  

4


 

NET SALES — SIX MONTHS ENDED JUNE 30, 2011
(in millions, unaudited)
                         
                    Constant  
    Net     Reported     Currency  
    Sales     % Growth     % Growth  
Geographic Segments
                       
Americas
  $ 1,238       1 %     1 %
Europe
    624       11       5  
Asia Pacific
    391       17       7  
 
                     
Total
    2,253       6       3  
 
                       
Product Categories
                       
Reconstructive
                       
Americas
    915       (1 )     (1 )
Europe
    495       9       3  
Asia Pacific
    289       16       5  
 
                     
Total
    1,699       5       1  
 
                       
Knees
                       
Americas
    544       (4 )     (4 )
Europe
    245       12       6  
Asia Pacific
    144       13       2  
 
                     
Total
    933       2       (1 )
 
                       
Hips
                       
Americas
    306       4       3  
Europe
    236       7        
Asia Pacific
    140       20       9  
 
                     
Total
    682       8       3  
 
                       
Extremities
    84       9       7  
 
                       
Dental
    130       20       18  
 
                       
Trauma
    139       18       14  
 
                       
Spine
    113       (4 )     (6 )
 
                       
Surgical and other
    172       12       7  

5


 

About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer’s 2010 sales were approximately $4.2 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
###
Website Information
We routinely post important information for investors on our website, www.zimmer.com, in the “Investor Relations” section. We intend to use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.
Note on Non-GAAP Financial Measures
As used in this press release, the term “adjusted” refers to operating performance measures that exclude inventory step-up, the provision for certain Durom® Acetabular Component product claims, special items and certain tax adjustments. Included in special items are acquisition and integration costs as well as employee termination benefits, certain contract terminations and asset impairment charges connected with global restructuring and transformation initiatives. The term “constant currency” refers to any financial measure that excludes the effect of changes in foreign currency exchange rates. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measure are included in this press release.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management’s beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” and “seeks” or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance

6


 

and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Corporate Integrity Agreement through 2012; the success of our quality and operational improvement initiatives; the outcome of the investigation by the U.S. government into Foreign Corrupt Practices Act matters announced in October 2007; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators; changes in tax obligations arising from tax reform measures or examinations by tax authorities; product liability and intellectual property litigation losses; the impact of health care reform measures in the U.S. including the impact of the new excise tax on medical devices, reductions in reimbursement levels from third-party payors and cost-containment efforts of health care purchasing organizations; our ability to retain the independent agents and distributors who market our products; and changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.

7


 

ZIMMER HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED JUNE 30, 2011 and 2010
(in millions, except per share amounts, unaudited)
                         
    2011     2010     % Inc/(Dec)  
Net Sales
  $ 1,137.4     $ 1,057.7       8 %
Cost of products sold
    287.9       250.6       15  
 
                   
Gross Profit
    849.5       807.1       5  
 
                   
Research and development
    57.0       54.2       5  
Selling, general and administrative
    469.9       438.3       7  
Certain claims
    50.0       75.0       (33 )
Special items
    13.5       11.5       17  
 
                   
Operating expenses
    590.4       579.0       2  
 
                   
Operating Profit
    259.1       228.1       14  
Interest expense, net
    9.8       14.3       (31 )
 
                   
Earnings before income taxes
    249.3       213.8       17  
Provision for income taxes
    45.5       48.3       (6 )
 
                   
Net Earnings of Zimmer Holdings, Inc.
  $ 203.8     $ 165.5       23  
 
                   
 
                       
Earnings Per Common Share
                       
Basic
  $ 1.06     $ 0.82       29  
Diluted
  $ 1.06     $ 0.82       29  
 
                       
Weighted Average Common Shares Outstanding
                       
Basic
    191.5       201.9          
Diluted
    192.7       203.0          
Certain amounts in the 2010 consolidated statement of earnings have been reclassified to conform to the 2011 presentation.

8


 

ZIMMER HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE SIX MONTHS ENDED JUNE 30, 2011 and 2010
(in millions, except per share amounts, unaudited)
                         
    2011     2010     % Inc/(Dec)  
Net Sales
  $ 2,253.0     $ 2,120.5       6 %
Cost of products sold
    566.9       519.0       9  
 
                   
Gross Profit
    1,686.1       1,601.5       5  
 
                   
Research and development
    112.6       104.7       8  
Selling, general and administrative
    928.2       885.5       5  
Certain claims
    50.0       75.0       (33 )
Special items
    39.0       14.1       176  
 
                   
Operating expenses
    1,129.8       1,079.3       5  
 
                   
Operating Profit
    556.3       522.2       7  
Interest expense, net
    20.8       28.9       (28 )
 
                   
Earnings before income taxes
    535.5       493.3       9  
Provision for income taxes
    122.8       122.4       0  
 
                   
Net Earnings of Zimmer Holdings, Inc.
  $ 412.7     $ 370.9       11  
 
                   
 
                       
Earnings Per Common Share
                       
Basic
  $ 2.15     $ 1.83       17  
Diluted
  $ 2.14     $ 1.82       18  
 
                       
Weighted Average Common Shares Outstanding
                       
Basic
    192.1       202.4          
Diluted
    193.3       203.6          
Certain amounts in the 2010 consolidated statement of earnings have been reclassified to conform to the 2011 presentation.

9


 

ZIMMER HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, unaudited)
                 
    June 30,     December 31,  
    2011     2010  
Assets
               
Current Assets:
               
Cash and cash equivalents
  $ 624.1     $ 668.9  
Short-term investments
    321.4       265.1  
Receivables, net
    888.4       775.9  
Inventories, net
    975.1       936.4  
Other current assets
    299.3       363.4  
 
           
Total current assets
    3,108.3       3,009.7  
 
               
Property, plant and equipment, net
    1,213.0       1,213.8  
Goodwill
    2,694.0       2,580.8  
Intangible assets, net
    811.5       827.1  
Other assets
    422.4       368.5  
 
           
Total Assets
  $ 8,249.2     $ 7,999.9  
 
           
 
               
Liabilities and Shareholders’ Equity
               
Current liabilities
  $ 679.0     $ 702.5  
Other long-term liabilities
    407.1       384.0  
Long-term debt
    1,147.3       1,142.1  
Shareholders’ equity
    6,015.8       5,771.3  
 
           
Total Liabilities and Shareholders’ Equity
  $ 8,249.2     $ 7,999.9  
 
           

10


 

ZIMMER HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2011 and 2010
(in millions, unaudited)
                 
    2011     2010  
Cash flows provided by (used in) operating activities
               
Net earnings of Zimmer Holdings, Inc.
  $ 412.7     $ 370.9  
Depreciation and amortization
    174.7       165.8  
Share-based compensation
    31.7       30.6  
Income tax benefits from employee stock compensation plans
    9.5       2.9  
Excess income tax benefits from employee stock compensation plans
    (3.6 )     (1.0 )
Inventory step-up
    7.8       1.3  
Changes in operating assets and liabilities, net of acquired assets and liabilities
               
Income taxes
    (11.5 )     (70.5 )
Receivables
    (76.0 )     (51.3 )
Inventories
    (21.8 )     27.5  
Accounts payable and accrued expenses
    (42.2 )     (37.4 )
Other assets and liabilities
    (48.1 )     93.4  
 
           
Net cash provided by operating activities
    433.2       532.2  
 
           
 
               
Cash flows provided by (used in) investing activities
               
Additions to instruments
    (85.2 )     (83.1 )
Additions to other property, plant and equipment
    (34.0 )     (26.7 )
Purchases of investments
    (186.7 )     (4.0 )
Sales of investments
    169.8       37.0  
Investments in other assets
    (26.4 )     (15.1 )
 
           
Net cash used in investing activities
    (162.5 )     (91.9 )
 
           
 
               
Cash flows provided by (used in) financing activities
               
Net proceeds under revolving credit facilities
    0.2        
Proceeds from employee stock compensation plans
    29.1       8.1  
Excess income tax benefits from employee stock compensation plans
    3.6       1.0  
Repurchase of common stock
    (357.2 )     (178.9 )
 
           
Net cash used in financing activities
    (324.3 )     (169.8 )
 
           
Effect of exchange rates on cash and cash equivalents
    8.8       (8.5 )
 
           
Increase (decrease) in cash and cash equivalents
    (44.8 )     262.0  
Cash and cash equivalents, beginning of period
    668.9       691.7  
 
           
Cash and cash equivalents, end of period
  $ 624.1     $ 953.7  
 
           

11


 

ZIMMER HOLDINGS, INC.
NET SALES BY GEOGRAPHIC SEGMENT
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2011 and 2010
(in millions, unaudited)
                                                 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2011     2010     % Inc     2011     2010     % Inc  
Americas
  $ 608.6     $ 609.3       %   $ 1,238.3     $ 1,225.0       1 %
Europe
    324.7       276.5       17       623.9       562.6       11  
Asia Pacific
    204.1       171.9       19       390.8       332.9       17  
 
                                       
Total
  $ 1,137.4     $ 1,057.7       8     $ 2,253.0     $ 2,120.5       6  
 
                                       
ZIMMER HOLDINGS, INC.
NET SALES BY PRODUCT CATEGORY
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2011 and 2010
(in millions, unaudited)
                                                 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2011     2010     % Inc/(Dec)     2011     2010     % Inc/(Dec)  
Reconstructive
                                               
Knees
  $ 470.9     $ 452.9       4 %   $ 933.1     $ 913.3       2 %
Hips
    345.0       317.1       9       682.3       632.8       8  
Extremities
    40.7       38.2       7       83.6       76.6       9  
 
                                       
 
    856.6       808.2       6       1,699.0       1,622.7       5  
 
                                       
 
                                               
Dental
    67.1       55.9       20       129.5       107.6       20  
Trauma
    69.1       57.8       20       139.2       118.2       18  
Spine
    56.4       57.9       (3 )     113.3       117.9       (4 )
Surgical and other
    88.2       77.9       13       172.0       154.1       12  
 
                                       
Total
  $ 1,137.4     $ 1,057.7       8     $ 2,253.0     $ 2,120.5       6  
 
                                       

12


 

ZIMMER HOLDINGS, INC.
RECONCILIATION OF REPORTED % GROWTH TO
CONSTANT CURRENCY % GROWTH
(unaudited)
                         
    For the Three Months Ended  
    June 30, 2011  
            Foreign     Constant  
    Reported     Exchange     Currency  
    % Growth     Impact     % Growth  
Geographic Segments
                       
Americas
    %     %     %
Europe
    17       12       5  
Asia Pacific
    19       13       6  
Total
    8       6       2  
Product Categories
                       
Reconstructive
                       
Americas
    (2 )           (2 )
Europe
    16       12       4  
Asia Pacific
    17       13       4  
Total
    6       6        
Knees
                       
Americas
    (5 )           (5 )
Europe
    21       12       9  
Asia Pacific
    14       12       2  
Total
    4       5       (1 )
Hips
                       
Americas
    2             2  
Europe
    12       13       (1 )
Asia Pacific
    20       13       7  
Total
    9       7       2  
Extremities
    7       3       4  
Dental
    20       4       16  
Trauma
    20       6       14  
Spine
    (3 )     3       (6 )
Surgical and other
    13       5       8  

13


 

ZIMMER HOLDINGS, INC.
RECONCILIATION OF REPORTED % GROWTH TO
CONSTANT CURRENCY % GROWTH
(unaudited)
                         
    For the Six Months Ended  
    June 30, 2011  
            Foreign     Constant  
    Reported     Exchange     Currency  
    % Growth     Impact     % Growth  
Geographic Segments
                       
Americas
    1 %     %     1 %
Europe
    11       6       5  
Asia Pacific
    17       10       7  
Total
    6       3       3  
 
                       
Product Categories
                       
Reconstructive
                       
Americas
    (1 )           (1 )
Europe
    9       6       3  
Asia Pacific
    16       11       5  
Total
    5       4       1  
 
                       
Knees
                       
Americas
    (4 )           (4 )
Europe
    12       6       6  
Asia Pacific
    13       11       2  
Total
    2       3       (1 )
 
                       
Hips
                       
Americas
    4       1       3  
Europe
    7       7        
Asia Pacific
    20       11       9  
Total
    8       5       3  
 
                       
Extremities
    9       2       7  
 
                       
Dental
    20       2       18  
 
                       
Trauma
    18       4       14  
 
                       
Spine
    (4 )     2       (6 )
 
                       
Surgical and other
    12       5       7  

14


 

ZIMMER HOLDINGS, INC.
Reconciliation of Net Earnings and Adjusted Net Earnings
For the Three Months Ended June 30, 2011 and 2010
(in millions, unaudited)
                 
    Three Months  
    Ended June 30,  
    2011     2010  
Net Earnings of Zimmer Holdings, Inc.
  $ 203.8     $ 165.5  
Inventory step-up
    3.4        
Certain claims
    50.0       75.0  
Special items
    13.5       11.5  
Taxes on inventory step-up, certain claims and special items and tax adjustments related to resolution of certain tax matters*
    (38.2 )     (30.8 )
 
           
Adjusted Net Earnings
  $ 232.5     $ 221.2  
 
           
 
*   The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.
ZIMMER HOLDINGS, INC.
Reconciliation of Net Earnings and Adjusted Net Earnings
For the Six Months Ended June 30, 2011 and 2010
(in millions, unaudited)
                 
    Six Months  
    Ended June 30,  
    2011     2010  
Net Earnings of Zimmer Holdings, Inc.
  $ 412.7     $ 370.9  
Inventory step-up
    7.8       1.3  
Certain claims
    50.0       75.0  
Special items
    39.0       14.1  
Taxes on inventory step-up, certain claims and special items and tax adjustments related to resolution of certain tax matters*
    (46.1 )     (32.7 )
 
           
Adjusted Net Earnings
  $ 463.4     $ 428.6  
 
           
 
*   The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.

15


 

ZIMMER HOLDINGS, INC.
Reconciliation of Diluted EPS and Adjusted Diluted EPS
For the Three Months Ended June 30, 2011 and 2010
(unaudited)
                 
    Three Months  
    Ended June 30,  
    2011     2010  
Diluted EPS
  $ 1.06     $ 0.82  
Inventory step-up
    0.02        
Certain claims
    0.26       0.37  
Special items
    0.07       0.05  
Taxes on inventory step-up, certain claims and special items and tax adjustments related to resolution of certain tax matters*
    (0.20 )     (0.15 )
Adjusted Diluted EPS
  $ 1.21     $ 1.09  
 
           
 
*   The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.
ZIMMER HOLDINGS, INC.
Reconciliation of Diluted EPS and Adjusted Diluted EPS
For the Six Months Ended June 30, 2011 and 2010
(unaudited)
                 
    Six Months  
    Ended June 30,  
    2011     2010  
Diluted EPS
  $ 2.14     $ 1.82  
Inventory step-up
    0.04       0.01  
Certain claims
    0.26       0.37  
Special items
    0.20       0.06  
Taxes on inventory step-up, certain claims and special items and tax adjustments related to resolution of certain tax matters*
    (0.24 )     (0.16 )
Adjusted Diluted EPS
  $ 2.40     $ 2.10  
 
           
 
*   The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.

16


 

ZIMMER HOLDINGS, INC.
Reconciliation of 2011 Projected Diluted EPS
and Projected Adjusted Diluted EPS
(unaudited)
                 
Projected Year Ended December 31, 2011:   Low     High  
Diluted EPS
    4.25       4.35  
Inventory step-up
    0.05       0.05  
Special items
    0.44       0.44  
Certain claims
    0.26       0.26  
Taxes on inventory step-up, certain claims and special items and tax adjustments related to resolution of certain tax matters*
    (0.30 )     (0.30 )
 
           
Adjusted Diluted EPS
  $ 4.70     $ 4.80  
 
           
 
*   The tax effect is calculated based upon the statutory rates for the jurisdictions where the items have or are projected to be incurred.

17